https://www.gosh.nhs.uk/news/new-commercial-agreement-for-gene-therapy-at-gosh/
New commercial agreement for gene therapy at GOSH
16 Mar 2023, 9:57 a.m.
Great Ormond Street Hospital for Children (GOSH) and Leucid Bio have entered a new commercial agreement to manufacture a gene therapy product.
Gene and cell therapies are the cutting-edge in clinical research for cancer treatments. They hold promise to offer personalised cancer treatments, including for rare forms that sadly affect children and young people. This year, GOSH opened new facilities for manufacturing gene and cell therapies. These facilities have increased our capacity to support development of cell and gene therapies from the very start in discovery research to clinical trials where therapies are tested in patients.
A new agreement with GOSH and Leucid Bio
In a new agreement, GOSH will work with Leucid Bio, a biotechnology company, at the state-of-the-art cleanroom facilities at the Zayed Centre for Research into Rare Disease in Children and provide quality assurance services required for manufacture of their gene therapy product, called LEU011.
LEU011 is a type of CAR T-cell therapy which reprogrammes these immune cells to recognise and destroy cancer cells. The company’s therapy has a particular structure on the cell surface that has been shown through early-stage research to work more effectively at targeting cancers than other types of CAR T-cell therapies.
Leucid Bio will submit for clinical trial approvals to trial LEU011, a type of gene therapy product over the next few months. In this first trial for patients, they hope to show that LEU011 improves outcomes and can save the lives of patients with solid tumours and blood cancers.
At Great Ormond Street Hospital, we see children with the most rare and complex cancers. There have been incredible strides forward in the treatment that we can offer, however, sadly for many these still don’t work. Gene therapies offer hope for better, and potentially curative treatments which is why we’re excited to support innovation in gene therapies through access to these highly specialist and unique facilities.“
We are extremely pleased to enter this first of its kind collaboration with GOSH to manufacture our lead asset, LEU011, for use in human studies. Additionally, we are pleased to have started a process with GOSH to examine the feasibility of applying our approach in the paediatric setting where there remains a great unmet need for new therapies.”
More information about CAR T-cell therapy
Raising awareness on Rare Disease Day
To celebrate Rare Disease Day we invited patients and their families to try out 13 different hands-on and interactive fun and educational science and research activities for children and adults.
Stem cells collected in late pregnancy herald advances in prenatal medicine
A new pioneering approach, developed by researchers at UCL and Great Ormond Street Hospital means human development can be observed in late pregnancy for the first time
A moment of discovery: extraordinary images showcase research at GOSH
A vibrant image helping researchers' study gastrointestinal diseases and their potential treatments has been crowned the winner of the 3rd annual National Institute for Health and Care Research Great Ormond Street Hospital Biomedical Research Centre (NIHR
172 years of leaps in medical science at GOSH
Today on Wednesday 14 February, GOSH is celebrating its 172nd birthday. With 2024 being a leap year, we wanted to look back at some of the leaps that we have made in medical science over the past 172 years